Daewoong Bio Designated as "Leading Company in Dementia Overcoming"

Development and Stable Supply of Pharmaceuticals in the Central Nervous System Field

Daewoong Bio announced on the 4th that it has been designated as a "Leading Company in Dementia Overcoming" by the Seoul Metropolitan Government and has received a commemorative plaque.

Jinsung Gon, CEO of Daewoong Bio (left), and Eunjeong Park, Deputy Director of Gangnam-gu Dementia Relief Center, are taking a commemorative photo at Daewoong Bio on the 3rd during the designation and plaque ceremony of the Dementia Overcoming Leading Company. Daewoong Bio

The "Leading Company in Dementia Overcoming" program is an initiative promoted by the National Dementia Center as part of the national dementia policy. Daewoong Bio was recognized for its contribution to creating a dementia-friendly social culture where patients and their families can live with peace of mind.

In June, Daewoong Bio employees participated in the "Dementia Partner" training held at the Gangnam-gu Dementia Relief Center in Seoul, joining efforts to foster a dementia-friendly environment. Through this training, they learned about dementia-related knowledge, prevention methods, and communication techniques with patients, developing empathy to better support patients and their families.

Daewoong Bio is focusing on the development of pharmaceuticals for dementia prevention and treatment, as well as stabilizing their supply. In particular, the company has achieved solid sales in its central nervous system (CNS) business, centered on cognitive function enhancers such as Gliatamin and Cerebrain, and the dementia treatment drug Beacept.

Notably, Gliatamin holds the top market share in the domestic choline alfoscerate segment. According to UBIST, a pharmaceutical market research agency, its prescription performance reached 154.5 billion won last year, making it the largest among products with the same ingredient. Additionally, it is available in various formulations, including capsules, injections, and syrups, providing patients with convenient administration and a wide range of treatment options.

Jinsung Gon, CEO of Daewoong Bio, stated, "This designation as a Leading Company in Dementia Overcoming is a recognition of Daewoong Bio's efforts to improve patient access to dementia treatments," adding, "We will continue to create tangible changes for patients and their families through the stable supply of dementia pharmaceuticals and diverse social contribution activities."

This content was produced with the assistance of AI translation services.